Insulet (FRA:GOV) Institutional Ownership : 85.14% (As of May. 16, 2024)

View and export this data going back to 2007. Start your Free Trial

What is Insulet Institutional Ownership?

Institutional ownership is the percentage of shares that are owned by institutions out of the total shares outstanding. As of today, Insulet's institutional ownership is 85.14%.

Insider Ownership is the percentage of shares that are owned by company insiders relative to the total shares outstanding. As of today, Insulet's Insider Ownership is 0.00%.

Float Percentage Of Total Shares Outstanding is the percentage of float shares relative to the total shares outstanding. As of today, Insulet's Float Percentage Of Total Shares Outstanding is 74.73%.

Insulet Institutional Ownership Historical Data

The historical data trend for Insulet's Institutional Ownership can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Insulet Institutional Ownership Chart

Insulet Historical Data

The historical data trend for Insulet can be seen below:

	2023-06-30	2023-07-31	2023-08-31	2023-09-30	2023-10-31	2023-11-30	2023-12-31	2024-01-31	2024-02-29	2024-03-31
Institutional Ownership	97.06	94.88	89.86	89.96	85.61	86.10	91.08	90.60	90.18	85.14

Insulet Institutional Ownership Calculation

The percentage of shares that are owned by institutions out of the total shares outstanding.

Insulet (FRA:GOV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Insulet Corp (FRA:GOV) » Definitions » Institutional Ownership

Comparable Companies

Traded in Other Exchanges

PODD:USA PODD:Mexico

Address

100 Nagog Park, Acton, MA, USA, 01720

Website

https://www.insulet.com

Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device and that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the U.S. Food and Drug Administration in 2005, approximately 360,000 insulin-dependent diabetics are using it worldwide.

Insulet (FRA:GOV) Headlines

No Headlines